Search PubMed⌕ Search

Biomedical subjects

D A Cheresh

Publications and source records attributed to D A Cheresh.

138 records · Page 8Linked to original sources
PubMed1985

Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis.

Monoclonal antibody MB3.6 (IgG3) recognizes disialoganglioside GD3, which represents a major surface marker on most human melanoma cells. We demonstrate that this antibody effectively lyses four human melanoma cell lines expressing significant levels of GD3 on their surface by either of two mechanisms: antibody-dependent cellular cytotoxicity (ADCC) or complement-mediated cytotoxicity. However, a melanoma cell line that expresses minimal levels of GD3 on 13% of the cells shows insignificant lysis by MB3.6 by either of these two mechanisms, suggesting that a threshold level of antigen expression may be required for effective in vitro cytolysis. In addition, monoclonal antibody (MAb) MB3.6 effectively inhibits establishment and growth of human melanoma tumors in the nude mouse when injected 24 hr after subcutaneous inoculation of tumor cells. Furthermore, MB3.6 produces specific regression of established melanoma tumors when injected 7 days after the subcutaneous inoculation of tumor cells. In contrast, tumor growth in animals injected with the melanoma cell line expressing minimal levels of GD3 was not affected by MAb MB3.6. These data indicate that once appropriate levels of the GD3 ganglioside are expressed on human melanoma cells, MAb MB3.6 can mediate tumor cell killing in vitro and in vivo and, thus, may prove useful for effective immunotherapy of human malignant melanoma.

Animals↗
PubMed1985

Characterization of a membrane surface glycoprotein associated with T-cell activation.

A cell surface antigen (gp140) was previously shown to exist on T cell subsets as well as on monocytes and macrophages in normal peripheral blood. Elevated expression of this antigen was associated with immune system disorders, acute lymphocytic leukemias, and in vitro activation of T cells. The antigen could be identified with monoclonal antibody (MAb) T305. Gp140 was a biosynthetic product of T cells because it could be labeled with [3H]leucine or [3H] glucosamine. Biochemical studies of gp140 used high performance liquid chromatography with nitrocellulose blotting to isolate aliquots suitable for 125I radiolabeling and immunoprecipitation to demonstrate: a) a reduction in m.w. of gp140 KD to 90 KD after deglycosylation by trifluoromethanesulfonic acid, b) alteration of isoelectric point from 4.1 to 5.7 after neuraminidase treatments, c) absence of N-linked sugars based on resistance to endoglycosidase F, d) resistance to trypsin and chymotrypsin digestion but susceptibility to pronase, and e) presence of sialic acid and lactosaminoglycan as O-linked sugars. Gp140 could be labeled with the periodate/NaB[3H]4 technique, indicating its similarity to a class of sialoglycoproteins previously described on activated T-cells in mouse and man. The antigenic epitope recognized by MAb T305 contains sialic acid linked (2----3) to galactose; however, periodate oxidation of the exocyclic ring of sialic acid did not affect binding by MAb T305. In an attempt to determine the functional role of gp140, we tested the ability of MAb T305 to block: a) proliferation of peripheral blood lymphocytes to mitogens, b) response to interleukin 2 (IL 2) of an IL 2 dependent T cell line, and c) growth of a T-ALL derived cell line. No inhibition of proliferation or growth was noted. Although the function of gp140 remains unknown, its association with lymphocyte activation and certain disease states suggests that it may provide a target for modulation of the immune response. These studies characterize the structural features of gp140 and further define the epitope recognized by MAb T305.

Animals↗
PubMed1984

O-acetylation of disialoganglioside GD3 by human melanoma cells creates a unique antigenic determinant.

Monoclonal antibody Mab D1.1 recognizes on human melanoma cells a ganglioside antigen characterized by an alkali-labile O-acetylated sialic acid residue. Immunochemical analysis showed that this molecule is an O-acetylated product of the neuroectoderm-associated disialoganglioside GD3. Controlled chemical O-acetylation of purified GD3 resulted in the generation of this same epitope. Lysates of human melanoma cells were found to contain O-acetyltransferase activity capable of generating the antigenic epitope recognized by Mab D1.1. Thus, the addition of a single O-acetyl group to a common cell surface-associated ganglioside can create a potentially tumor-specific antigen.

Acetylation↗
PubMed1984

A monoclonal antibody recognizes an O-acylated sialic acid in a human melanoma-associated ganglioside.

Monoclonal antibody D1.1 originally prepared against the B49 cell line derived from a rat brain tumor was shown to react with a ganglioside present in fetal rat brain. We have found that this antigen is also present in human malignant melanoma tumors as well as many melanoma cell lines. The ganglioside from human melanoma cell lines migrates between GM1 and GM2 on one-dimensional thin layer chromatography. Analysis by two-dimensional thin layer chromatography with intermediate ammonia treatment suggests that the ganglioside contains one or more base-labile O-acyl esters. Mild base hydrolysis under conditions known to remove O-acyl esters results in complete loss of antigenic reactivity. Thus, the alkali-labile moiety is a critical component of the epitope recognized by the antibody. Analysis of the sialic acids of total gangliosides from [6-3H]glucosamine-labeled melanoma cells showed that approximately 10% of these molecules are O-acylated. Similar analysis of the purified ganglioside showed that greater than 30% of the sialic acids comigrated with authentic 9-O-acetyl-N-acetylneuraminic acid. The antibody did not cross-react with normal human skin melanocytes nor with any of a large number of normal human adult and fetal tissues. The antibody also did not react with numerous other malignant cell lines studied. These findings suggest that the antigenic epitope defined by antibody D1.1 contains an O-acylated sialic acid and may arise from aberrant O-acetylation occurring in human malignant melanoma cells.

Animals↗
PubMed1984

Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells.

The predominant gangliosides produced by two cultured human melanoma cell lines are GD3 and/or GD2. These gangliosides were found to be cell associated and present in substratum-attached material after cell removal by EDTA. Monoclonal antibodies directed to GD2 and GD3 specified the cell-surface distribution of these gangliosides and localized them in focal adhesion plaques at the interface of cells and their substratum. These attachment sites did not represent indiscriminant membrane fragments remaining after removal of cells with EDTA, because neither melanoma-associated proteoglycan nor class I histocompatibility antigens were detected by their respective antibodies. Our data suggest that the disialogangliosides GD2 and GD3 may be involved in the interaction between human melanoma cells and solid substrata.

Cell Adhesion↗
PubMed1984

Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients.

A murine monoclonal antibody (monoclonal antibody 126) produced against cultured human neuroblastoma cells (LAN-1) was found to be specifically directed to a disialoganglioside (GD2) antigen preferentially expressed on both cell lines and tissues derived from melanoma and neuroblastoma. In enzyme-linked immunosorbent assays, monoclonal antibody 126 failed to react with leukemic and lymphoblastoid cells as well as with a variety of carcinoma and sarcoma cell lines. Immunohistological analysis by the immunoperoxidase technique revealed strong reactivity of monoclonal antibody 126 with frozen and formaldehyde-fixed neuroblastoma and melanoma tissues. Tissues from patients with glioma or with small cell cancer of the lung showed faint staining, whereas those from individuals with sarcoma, lymphoma, and a variety of other neoplasms proved to be negative. Sera of neuroblastoma patients showed significantly elevated GD2 levels compared to normal children (p less than 0.001) and children with other tumors (p less than 0.001) as determined by a quantitative competitive enzyme-linked immunosorbent assay. Furthermore, the GD2 serum level of one neuroblastoma patient, when followed serially, was found to correlate with progression of disease, suggesting the potential usefulness of this assay for the diagnosis and monitoring of neuroblastoma.

Antibodies, Monoclonal↗
PubMed1984

Interaction of an acute phase reactant, alpha 1-acid glycoprotein (orosomucoid), with the lymphoid cell surface: a model for non-specific immune suppression.

alpha 1-Acid glycoprotein (AG), a serum component elevated during acute inflammation, has been implicated in the suppression of various immunological responses. Pretreatment of lymphoid cells with AG at a concentration commonly found in patients with acute inflammation results in the inhibition of mitogen induced lymphoproliferation as well as capping of concanavalin A (Con A) receptors and surface immunoglobulin (sIg) on the lymphoid cell surface. In order to determine a potential interaction of AG with the lipid bilayer we examined the effects of purified AG on synthetic phosphatidyl choline vesicles. AG displaces 1-anilino-8-naphthalene sulphonate (ANS), an anionic surface probe from these vesicles yet is unable to perturb the binding of N-phenyl-1-naphthalamine (NPN), a hydrophobic probe of the membrane interior. The non-immunosuppressive asialo-derivative of AG is incapable of displacing ANS from the vesicles. The interaction of AG with the membrane may partially involve electrostatic forces mediated by sialic acid and/or steric hindrance of receptor mobility. The results suggest that AG has the capacity to perturb the lymphoid cell surface and interfere with events required for lymphocyte proliferation.

1-Naphthylamine↗
PubMed1983

Blocked herpes simplex virus type 2-specific DNA synthesis in simian virus 40-transformed hamster cells permissive for herpes simplex virus type 1.

Simian virus 40-transformed hamster cells (LL-1) permissive to herpes simplex virus type 1 (HSV-1) were shown to be relatively nonpermissive to HSV-2. When LL-1 cells were infected with HSV-2, there was a 3- to 4-log reduction in infectious viral progeny at 24 h postinfection as compared with HSV-1 under identical cultured conditions. HSV-2 could be carried in the LL-1 cell line for up to 12 passages without any appreciable cytopathology. Various early functions of the replicative cycle of HSV-2 appeared to be normal. Experiments demonstrated that early enzyme activity, HSV-2 thymidine kinase, and DNA polymerase appeared at permissive levels in extracts of HSV-2-infected LL-1 cells. However, DNA analysis of HSV-2 infected LL-1 cells demonstrated a block in HSV-2-specific DNA synthesis, although HSV-2 was capable of inhibiting DNA synthesis in LL-1 cells. Furthermore, indirect immunofluorescence studies indicate that late HSV-2 structural protein synthesis was inhibited in infected LL-1 cells. Thus, the inability of HSV-2 to replicate in LL-1 cells is due to a block at or before HSV-specific DNA synthesis, resulting in a reduction of the structural protein synthesis required for viral maturation.

Animals↗
PubMed1982

Maximizing differences in the concanavalin A-induced blastogenic responses of lymphocytes from breast cancer patients and controls by the use of alpha-methyl-D-mannoside.

In an attempt to magnify differences in the immune responses of potentially immunosuppressed cancer patients and normal controls, an assessment was made on the effects of the competitive inhibitor alpha-methyl-D-mannoside on the concanavalin A (Con A)-induced blastogenic responses of lymphocytes from each of these populations. Lymphocytes from breast cancer patients with metastatic disease were significantly deficient in their capability to undergo blast transformation regardless of whether the monosaccharide inhibitor was added to the assay cultures. In contrast, lymphocytes from breast cancer patients who did not display metastatic disease were capable of normal blastogenic responses to Con A. The addition of alpha-methyl-D-mannoside to lymphocyte cultures caused a significantly greater inhibition of the blastogenic responses of these patients' cells as compared to cells of normal controls. Thus the monosaccharide seems to serve as a useful reagent for optimizing differences between lymphocyte blastogenic responses of normal donors and those of immunodepressed donors. The results suggest that lymphocytes from breast cancer patients without clinically evident metastases possess some modification of their cell membrane. One possibility discussed was that the number or distribution of receptors for Con A on the membrane of lymphocytes of these patients is deficient.

Binding, Competitive↗
PubMed1982

Mitogen-induced blastogenesis and receptor mobility inhibition by breast cancer serum with elevated orosomucoid (alpha 1-acid glycoprotein) levels.

Sera from cancer patients have been shown to suppress normal lymphoid cell responsiveness in vitro. In the present study, sera from breast cancer patients were demonstrated to be inhibitory to the concanavalin A (Con A)-, Proteus vulgaris-derived phytohemagglutinin-, and pokeweed mitogen-induced blastogenic responses of normal lymphoid cells. Orosomucoid (OR) (alpha 1-acid glycoprotein), an acute-phase reactant, was elevated in these sera, and a positive correlation existed between the OR level in the sera and its immunosuppressive capacity. When normal lymphoid cells were reached in fluorescein isothiocyanate-labeled Con A, cells that had been preincubated in breast cancer sera known to contain an elevated level of OR showed a significant decrease in Con A receptor mobility as compared to the receptor mobility of the same lymphoid cells preincubated in normal sera. Thus a component(s) from the sera of the breast cancer patients had the capacity to inhibit lymphocyte activation. This inhibition might have resulted from an interaction of OR with the membrane.

Breast Neoplasms↗